Analysts expect that Intersect ENT, Inc. (NASDAQ:XENT) will post sales of $27.52 million for the current quarter, Zacks reports. Eight analysts have made estimates for Intersect ENT’s earnings, with the highest sales estimate coming in at $27.98 million and the lowest estimate coming in at $26.48 million. Intersect ENT posted sales of $24.23 million during the same quarter last year, which suggests a positive year over year growth rate of 13.6%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, February 27th.
On average, analysts expect that Intersect ENT will report full-year sales of $27.52 million for the current financial year, with estimates ranging from $91.70 million to $94.74 million. For the next fiscal year, analysts anticipate that the firm will report sales of $112.85 million per share, with estimates ranging from $108.88 million to $118.99 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover Intersect ENT.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. The business had revenue of $22.31 million during the quarter, compared to analysts’ expectations of $21.53 million. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The business’s revenue was up 20.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.22) earnings per share.
XENT has been the subject of a number of recent analyst reports. Canaccord Genuity boosted their price objective on Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. Piper Jaffray Companies restated a “buy” rating and issued a $35.00 price objective on shares of Intersect ENT in a research report on Tuesday, August 22nd. Northland Securities restated a “hold” rating and issued a $25.00 price objective on shares of Intersect ENT in a research report on Friday, November 3rd. Bank of America Corporation boosted their price objective on Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Finally, Deutsche Bank AG set a $31.00 price objective on Intersect ENT and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $30.88.
TRADEMARK VIOLATION WARNING: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/11/14/brokerages-expect-intersect-ent-inc-xent-will-announce-quarterly-sales-of-27-52-million.html.
In related news, COO Richard E. Kaufman sold 22,425 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $30.22, for a total transaction of $677,683.50. Following the completion of the sale, the chief operating officer now directly owns 149,821 shares in the company, valued at $4,527,590.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $31.05, for a total value of $398,464.65. Following the sale, the chief financial officer now owns 27,833 shares of the company’s stock, valued at $864,214.65. The disclosure for this sale can be found here. Insiders have sold 114,563 shares of company stock valued at $3,383,447 over the last quarter. 13.70% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc boosted its stake in Intersect ENT by 3.8% during the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after buying an additional 255 shares during the last quarter. American International Group Inc. boosted its stake in Intersect ENT by 7.1% during the first quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock worth $269,000 after buying an additional 1,037 shares during the last quarter. Voya Investment Management LLC boosted its stake in Intersect ENT by 9.7% during the second quarter. Voya Investment Management LLC now owns 12,724 shares of the medical equipment provider’s stock worth $356,000 after buying an additional 1,128 shares during the last quarter. Rhumbline Advisers boosted its stake in Intersect ENT by 5.9% during the second quarter. Rhumbline Advisers now owns 29,396 shares of the medical equipment provider’s stock worth $822,000 after buying an additional 1,625 shares during the last quarter. Finally, EAM Investors LLC boosted its stake in Intersect ENT by 1.1% during the third quarter. EAM Investors LLC now owns 164,267 shares of the medical equipment provider’s stock worth $5,117,000 after buying an additional 1,776 shares during the last quarter. 80.23% of the stock is currently owned by institutional investors.
Intersect ENT (NASDAQ:XENT) traded up $0.45 during trading on Friday, hitting $28.60. The stock had a trading volume of 293,400 shares, compared to its average volume of 292,953. Intersect ENT has a 1-year low of $9.20 and a 1-year high of $33.25.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.